2018 Hepatic Insufficiency Drug Development- Pipeline Analysis Report
Hepatic Insufficiency is a rare disease that can either present slow or rapid worsening of liver functioning. Young population is the most affected age group. The disease presents high mortality rates. Hepatitis infection, medication issues, alcohol are the primary reasons of the disease.
Over 30 companies and universities are focusing on developing treatment options for Liver Failure (Hepatic Insufficiency).
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Liver Failure (Hepatic Insufficiency) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Liver Failure (Hepatic Insufficiency) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Liver Failure (Hepatic Insufficiency) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Over 30 companies and universities are focusing on developing treatment options for Liver Failure (Hepatic Insufficiency).
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Liver Failure (Hepatic Insufficiency) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Liver Failure (Hepatic Insufficiency) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Liver Failure (Hepatic Insufficiency) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 HEPATIC INSUFFICIENCY PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hepatic Insufficiency Pipeline Snapshot
2.3 Hepatic Insufficiency Pipeline by Phase
2.4 Hepatic Insufficiency Pipeline by Company
2.5 Hepatic Insufficiency Pipeline by Mechanism of Action
3 HEPATIC INSUFFICIENCY- COMPANY WISE PIPELINE ANALYSIS
BioLineRx
Cell2B
HepaRegeniX GmbH
Martin Pharmaceuticals
Mina Therapeutics
Novartis AG
PledPharma AB
Promethera Biosciences
Proterris Inc
Steminent Biotherapeutics Inc
Therapure Biopharma
Unicyte AG
Versantis AG
Vital Therapies Inc
Xenexus Pharmaceuticals
4 HEPATIC INSUFFICIENCY R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HEPATIC INSUFFICIENCY PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 HEPATIC INSUFFICIENCY PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hepatic Insufficiency Pipeline Snapshot
2.3 Hepatic Insufficiency Pipeline by Phase
2.4 Hepatic Insufficiency Pipeline by Company
2.5 Hepatic Insufficiency Pipeline by Mechanism of Action
3 HEPATIC INSUFFICIENCY- COMPANY WISE PIPELINE ANALYSIS
BioLineRx
Cell2B
HepaRegeniX GmbH
Martin Pharmaceuticals
Mina Therapeutics
Novartis AG
PledPharma AB
Promethera Biosciences
Proterris Inc
Steminent Biotherapeutics Inc
Therapure Biopharma
Unicyte AG
Versantis AG
Vital Therapies Inc
Xenexus Pharmaceuticals
4 HEPATIC INSUFFICIENCY R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HEPATIC INSUFFICIENCY PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Hepatic Insufficiency Pipeline by Phase, H1- 2018
Figure 2: Hepatic Insufficiency Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Hepatic Insufficiency Pipeline by Phase, H1- 2018
Figure 2: Hepatic Insufficiency Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Hepatic Insufficiency Pipeline by Phase, H1- 2018
Table 2: Hepatic Insufficiency Pipeline by Companies, H1- 2018
Table 3: Hepatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Table 4: BioLineRx Hepatic Insufficiency pipeline, May 2018
Table 5: Cell2B Hepatic Insufficiency pipeline, May 2018
Table 6: HepaRegeniX GmbH Hepatic Insufficiency pipeline, May 2018
Table 7: Martin Pharmaceuticals Hepatic Insufficiency pipeline, May 2018
Table 8: Mina Therapeutics Hepatic Insufficiency pipeline, May 2018
Table 9: Novartis AG Hepatic Insufficiency pipeline, May 2018
Table 10: PledPharma AB Hepatic Insufficiency pipeline, May 2018
Table 11: Promethera Biosciences Hepatic Insufficiency pipeline, May 2018
Table 12: Proterris Inc Hepatic Insufficiency pipeline, May 2018
Table 13: Steminent Biotherapeutics Inc Hepatic Insufficiency pipeline, May 2018
Table 14: Therapure Biopharma Hepatic Insufficiency pipeline, May 2018
Table 15: Unicyte AG Hepatic Insufficiency pipeline, May 2018
Table 16: Versantis AG Hepatic Insufficiency pipeline, May 2018
Table 17: Vital Therapies Inc Hepatic Insufficiency pipeline, May 2018
Table 18: Xenexus Pharmaceuticals Hepatic Insufficiency pipeline, May 2018
Table 1: Hepatic Insufficiency Pipeline by Phase, H1- 2018
Table 2: Hepatic Insufficiency Pipeline by Companies, H1- 2018
Table 3: Hepatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Table 4: BioLineRx Hepatic Insufficiency pipeline, May 2018
Table 5: Cell2B Hepatic Insufficiency pipeline, May 2018
Table 6: HepaRegeniX GmbH Hepatic Insufficiency pipeline, May 2018
Table 7: Martin Pharmaceuticals Hepatic Insufficiency pipeline, May 2018
Table 8: Mina Therapeutics Hepatic Insufficiency pipeline, May 2018
Table 9: Novartis AG Hepatic Insufficiency pipeline, May 2018
Table 10: PledPharma AB Hepatic Insufficiency pipeline, May 2018
Table 11: Promethera Biosciences Hepatic Insufficiency pipeline, May 2018
Table 12: Proterris Inc Hepatic Insufficiency pipeline, May 2018
Table 13: Steminent Biotherapeutics Inc Hepatic Insufficiency pipeline, May 2018
Table 14: Therapure Biopharma Hepatic Insufficiency pipeline, May 2018
Table 15: Unicyte AG Hepatic Insufficiency pipeline, May 2018
Table 16: Versantis AG Hepatic Insufficiency pipeline, May 2018
Table 17: Vital Therapies Inc Hepatic Insufficiency pipeline, May 2018
Table 18: Xenexus Pharmaceuticals Hepatic Insufficiency pipeline, May 2018
